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USE OF THE PATIENT ANALYSIS & TRACKING
SYSTEM (PATS) IN ASSESSMENT OF RATIONAL
PHARMACOTHERAPY OF DIABETICS IN A BIG
HOSPITAL
Sechser T, Haèkajlo D
Institute for Clinical and Experimental Medicine, Prague,
Czech Republic
OBJECTIVE: The aim of the pilot retrospective study 
was to implement PATS in the process of evaluation of
pharmacotherapy of hospitalized diabetics. In 3-months
cycles, collected data on pharmacotherapy were com-
pared with clinical guidelines and hospital formulary.
METHODS: In 148 hospitalized diabetics with the most
frequent diagnosis E107 (diabetes mellitus with multi-
organ complications) were collected data on pharma-
cotherapy in 3-months cycles. Data collected from
patients’ charts included clinical diagnosis, all adminis-
tered drugs and their dosage forms, single and daily-
prescribed doses. Those data were entered via custom-
made software module in the form of drug-chart into the
clinical information system PATS (Patient Analysis and
Tracking System). The basic data were programmatically
processed to a standard PATS registry for further analy-
sis. The data on drugs prescription were retrieved using
the ATC classiﬁcation. These data were compared both
with the clinical guidelines used in the department and
hospital formulary. RESULTS: According to the 3 digital
ATC codes, the prescribed drugs were from 53 different
groups. The most frequently prescribed drugs were drugs
used in diabetes (313 drugs including insulins), the fol-
lowing groups are ordered according to the frequency 
of use: antibiotics (123), diuretics (92), antithrombotic
agents (89), and agents acting on the renin-angiotensin
system (73). The further analysis has shown that there is
a great variability in pharmacotherapy in patients with
the same diagnosis, e.g. 7 different ACE inhibitors were
administered to the patients. CONCLUSION: PATS is a
very useful and ﬂexible tool in assessment of rational
pharmacotherapy of hospitalized patients.
EAR, EYE & SKIN DISEASES/DISORDERS—
Economic Outcomes
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COST OF ILLNESS OF GLAUCOMA IN CANADA:
ANALYSES BASED ON VISUAL FIELD
MEASUREMENTS AND PHYSICIAN’S
ASSESSMENT
Iskedjian M1,Walker JH2,Vicente C1,Trope G3, Buys Y3,
Einarson T4, Covert D5
1PharmIdeas Research and Consulting Inc, Oakville, ON,
Canada; 2Brock University, St. Catharines, ON, Canada;
3Toronto Western Hospital,Toronto, ON, Canada; 4University
of Toronto,Toronto, ON, Canada; 5Alcon Labs, Forth Worth,
TX, USA
OBJECTIVE: A longitudinal, retrospective study was 
performed to investigate the cost of illness attributed 
to primary open angle glaucoma (POAG). METHODS:
Patients were identiﬁed using ICD-9 code 365.11. Three-
year data associated with POAG were collected from
patient charts in two clinics by a reviewer using a data
collection form. A second reviewer veriﬁed data entry,
including visual ﬁeld (VF) mean deviation (MD), physi-
cian’s assessment (PA), and resource utilization (physician
visits, procedures, and medications). VF was classiﬁed
mild (MD < 5dB), moderate (5 ≥ MD < 12dB), or severe
(MD ≥ 12dB); and PA as stable, uncontrolled, or delayed
stable (uncontrolled for 12 months, then stable).
Resources were costed in Canadian dollars from the 
Ministry of Health perspective using standard lists. Costs
were summed for each patient, then contrasted between
groups using ANOVA with Scheffe’s post-hoc test 
(a = 0.05). RESULTS: Of 411 patient charts extracted,
235 provided useable data (mean follow-up 4 years); 35
excluded patients had ocular comorbidities, 141 had
insufﬁcient follow-up data (<3 years). Mean costs (SD)
for VF groups mild (n = 80), moderate (n = 81), and
severe (n = 74) were $376 ($279), $493 ($314), and $586
($251), respectively. Analysis by PA for stable (n = 115),
uncontrolled (n = 62), and delayed stable (n = 58) yielded
costs of $437 ($269), $506 ($320), and $547 ($306),
respectively. In the VF analysis, differences were signiﬁ-
cant (p < 0.05) between all groups for the ﬁrst half of 
the follow-up period and between mild and severe for 
the entire follow-up period. For PA, the mean cost of the
stable group was the lowest, without however signiﬁcant
differences. DISCUSSION and CONCLUSIONS: The
cost of treating POAG increases with severity, especially
when applying VF categories. Hence, severity in terms of
VF score may give an indication of the magnitude of the
expected total cost. Further examination of the relation-
ship between VF and other clinical parameters, such as
intra-ocular pressure, is warranted.
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MEDICAL PREDICTIVE FACTORS OF
GLAUCOMA TREATMENT COSTS IN FRANCE
Denis P1, Lafuma A2, Berdeaux G3
1Hopital Edouard Herriot, Lyon, France; 2Cemka, Bourg-
La-Reine, France; 3Alcon, Rueil-Malmaison, France
OBJECTIVES: To describe the patterns and the eco-
nomics of glaucoma treatment. METHODS: Ophthal-
mologists selected at random had to include 4 consecutive
patients older than 18 seen in consultation during a week,
2 with glaucoma and 2 with ocular hypertension (OH).
Socio-demographics, general and eye comorbidities, glau-
coma risk factors, clinical data, and medical item con-
sumption over the previous 5 years were collected. The
economic perspective was society’s. Predictive medical
factors of costs were identiﬁed using a stepwise regres-
sion. RESULTS: 84 ophthalmologists included 337
patients who were 60% female with a mean age of 62;
34.1% had OH and 35.9% were still receiving ﬁrst line
treatment. Glaucoma patients were older and no differ-
ence was found on confounding factors. Patients with
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glaucoma visited practitioners more often (+0.74 / year),
had more exams (0.42), and were more likely to be using
drug combinations (+28.5%) and to be hospitalised
(+16.2%). Drugs represented the bulk of the expenses 
followed by exams and ofﬁce visits. Two main clinical
factors contributed to costs: abnormalities of the papilla
due to the presence of glaucoma (+ EURO 96.43) and the
number of treatment switches (+ EURO 127.62 / switch).
These were followed by IOP (+ EURO 7.08 / mmHg) and
VA (+ EURO 41.37 / 2 Lines lost VA). In comparison to
work conducted in the mid-nineties, drug costs increased
while hospital costs decreased, although methodologies
were different. CONCLUSION: Two independent factors
explained the bulk of total cost variance: the presence of
glaucoma and therapy switches. They contributed inde-
pendently in an additive way to total cost. Under isotropic
hypotheses, effective early treatment strategies aimed at
postponing the effects of glaucoma and controlling IOP
are expected to be cost saving in the long-term.
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LIFE-LONG SOCIETAL NET VALUE OF
GLAUCOMA TREATMENT:A MARKOV MODEL
APPROACH
Lafuma A1, Pradet S1, Berdeaux G2
1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison,
France
OBJECTIVE: To assess and to identify the key variables
of the life-long societal net value of glaucoma treatment.
METHODS: A Markov model was used to reproduce the
average discounted cost of glaucoma treatment over 40
years in France on a 47-year-old cohort (52% female).
Clinical states were ﬁrst to fourth line treatment, no treat-
ment, laser, surgery, blindness and death. All patients
started ﬁrst line, went successively to the next line after
failure. After each failure (and always after the fourth
line) patients could have either laser or surgery followed
by no treatment, or a new ﬁrst line treatment. Transition
probabilities and resource utilisation came from of a
cross-sectional study with 5 years retrospective data col-
lection for the glaucoma treatment, and from national
statistics. In-patient and out-patient direct medical costs
and indirect costs were estimated from a societal point 
of view. The discount rate was ﬁxed at 5%. Sensitivity
analyses and second order Monte-Carlo simulation were
performed. RESULTS: Life expectancy of this cohort was
32.5 years. Discounted total cost was €6,990 compared
to €14,133 without discounting. Patients spent 12.3 years
in ﬁrst line, 5.1 in second, 3.9 in third, and 3.2 in fourth,
and 5.7 without treatment. They had 1.1 laser treatments
and 1.2 surgeries on average. They were legally blind for
2.1 years on average. Increasing ﬁrst line treatment dura-
tion by 25% would reduce discounted total cost to
€6,709, or €13,368 without discounting. Patients would
stay 1.9 years more in ﬁrst line, 0.8 years less in second,
0.6 years less in third, 0.6 years less in fourth and 0.3
years less without treatment. The use of surgery and laser
would decrease by 10%. CONCLUSION: Increasing 
ﬁrst line glaucoma treatment duration is a cost saving
approach over life of a patient according to our model.
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A DISEASE SEVERITY STAGING SYSTEM FOR
MEASURING THE COST OF GLAUCOMA
PROGRESSION IN EUROPE
Doyle J1,Amaya K1, Casciano J1, Kotak S1, Buchholz P2,
Walt J3
1The Analytica Group, New York, NY, USA; 2Allergan,
Ettlingen, Germany; 3Allergan, Irvine, CA, USA
OBJECTIVES: In order to conduct a multi-national 
retrospective chart review with the purposes of assessing
resource utilization and costs associated with disease pro-
gression in Europe, a glaucoma staging system (GSS) was
needed. To date no universally accepted GSS exists, par-
ticularly one that takes into account economic consider-
ations. We developed and tested a modiﬁed system to
allow for unambiguous stage assignment of patients expe-
riencing varied severity of disease. METHODS: A review
of currently developed GSSs was conducted and the
Bascom Palmer GSS was selected as most adaptable for
economic analyses. A modiﬁed-Delphi panel of physicians
specializing in glaucoma treatment suggested modiﬁca-
tions to the system, with the end goal of assessing the eco-
nomic impact of treating glaucoma. Three centers were
identiﬁed in each of the four participating countries:
France, Germany, Italy and U.K. Approximately 12
charts per center were selected based on the inclusion/
exclusion criteria described in the study protocol. The
revised GSS was applied on all identiﬁed charts to clas-
sify patients by disease severity. Clinical and demographic
data were obtained from the charts and national-level
ﬁnancial data were obtained from health economists in
each country. RESULTS: The ﬁnal GSS comprises six
stages based principally on visual ﬁeld parameters. End-
stage disease deﬁnition was based on poor visual acuity
and inability to perform visual ﬁelds. The staging system
was able to classify over 100 identiﬁed charts of glaucoma
patients from normal to end-stage disease, and facilitated
resource utilization abstraction by individual stage.
CONCLUSIONS: An improved GSS to track progression
was designed which allows staging of patients from his-
torical chart data. This GSS may be used to monitor long-
term progression and is a useful tool for the purposes of
assessing the economic impact of glaucoma progression.
The tool should be tested prospectively to determine its
ultimate utility in clinical practice.
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COST-UTILITY ANALYSIS OF TIMOLOL VERSUS
LATANOPROST VERSUS TRAVOPROST IN THE
TREATMENT OF GLAUCOMA AND OCULAR
HYPERTENSION
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